Fred Alger Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-5,211
Closed -$104K – 409
2024
Q3
$104K Sell
5,211
-1,334
-20% -$20.7K ﹤0.01% 405
2024
Q2
$73.2K Sell
6,545
-3,889
-37% -$32.6K ﹤0.01% 407
2024
Q1
$68.9K Hold
10,434
– – ﹤0.01% 428
2023
Q4
$47.2K Sell
10,434
-945,576
-99% -$3.5M ﹤0.01% 431
2023
Q3
$3.42M Sell
956,010
-1,826,199
-66% -$7.03M 0.02% 281
2023
Q2
$10.3M Buy
2,782,209
+764,615
+38% +$2.83M 0.05% 193
2023
Q1
$6.68M Sell
2,017,594
-10,773
-0.5% -$37.2K 0.04% 230
2022
Q4
$7.87M Sell
2,028,367
-835,851
-29% -$2.58M 0.04% 229
2022
Q3
$6.96M Buy
+2,864,218
New +$6.87M 0.04% 229

Other funds holding ADMA

Fred Alger Management's ADMA Position: Q4 2024 in Review

Fred Alger Management sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 5,211 shares — an estimated $104K sold.

Fred Alger Management first reported a position in ADMA in Q3 2022 and held it in 9 quarters. The position peaked at $10.3M in Q2 2023. 322 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

  • Fred Alger Management reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
  • Fred Alger Management sold 5,211 ADMA Biologics shares in Q4 2024, an estimated $104K.
  • Fred Alger Management first reported a position in ADMA Biologics in Q3 2022 and held it in 9 quarters.
  • Fred Alger Management's ADMA Biologics position peaked at $10.3M in Q2 2023.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on Fred Alger Management's 13F filing for Q4 2024, filed 14 Feb 2025.